Krystal Biotech stock rises 15.8% in a month with strong sales and growth prospects.

From Nasdaq: 2025-03-08 03:34:00

Shares of Krystal Biotech (KRYS) have outperformed the industry, sector, and S&P 500, gaining 15.8% in the past month. The company reported strong uptake of Vyjuvek, its gene therapy for DEB, with sales reaching $290.5 million in 2024. Krystal is also making progress in expanding Vyjuvek’s approval to other geographies.

Krystal has secured over 510 reimbursement approvals for Vyjuvek in the US and is seeking approval in Europe and Japan. The company is also progressing its pipeline with candidates for cystic fibrosis, AATD, and solid tumors of the lung. Positive results from ongoing studies are expected in 2025, boosting future growth prospects.

Krystal’s stock is considered a good buy with strong fundamentals and growth potential. The company’s cash balance of $749.6 million provides a solid foundation for developing its pipeline. Analysts have increased earnings estimates for 2025 and 2026, reflecting positive sentiment towards the stock.

Investors looking for opportunities in the biotech sector may also consider Gilead Sciences (GILD) and BioMarin Pharmaceutical (BMRN), both ranked #2 (Buy). These companies have seen positive earnings estimate revisions for 2025 and 2026, indicating potential for growth. GILD and BMRN have a track record of beating earnings estimates, making them attractive investment options.



Read more at Nasdaq: Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?